Can a simple blood test improve treatment for a common cause of high blood pressure?

NCT ID NCT06108427

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to dose a common blood pressure medication (MRA) for people with primary aldosteronism, a condition where the body makes too much aldosterone. Doctors will use a blood test for renin, a hormone, to guide dosing. The goal is to see if this leads to better control and fewer side effects. About 58 adults with newly diagnosed primary aldosteronism will be randomly assigned to either renin-guided or standard care for 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mineralocorticoid receptor antagonists (MRA)
What this could lead to
If successful, this approach could make MRA treatment safer and more effective for people with primary aldosteronism, reducing side effects while controlling blood pressure.
What could go wrong
This is a small feasibility study, so results may not apply to everyone. The renin-guided method may not improve outcomes or could be harder to implement in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital du Sacré-Coeur de Montréal

    RECRUITING

    Montreal, Quebec, H4J1C5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.